ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Monday, November 13, 2023

2:00PM-3:30PM: Abstract Number: 1600

Transcriptomic Characterization of Class II Lupus Nephritis and Outcomes

Abstracts: SLE – Etiology & Pathogenesis

2:00PM-3:30PM: Abstract Number: 1653

Up or Down: Does Direction of Stair Climbing Difficulty Matter for Incident Functional Limitation and Knee Replacement in Knee Osteoarthritis?

Abstracts: Interprofessional Exemplary

2:00PM-3:30PM: Abstract Number: 1655

Usability Testing of JIActiv, an Instagram-Based Program Promoting Engagement in Physical Activity Among Young People Living with Juvenile Idiopathic Arthritis

Abstracts: Interprofessional Exemplary

4:00PM-5:30PM: Abstract Number: 1691

16-Week Results from FOREMOST, a Placebo-Controlled Study Involving Oligoarticular Psoriatic Arthritis Treated with Apremilast

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: PsA

4:00PM-5:30PM: Abstract Number: 1686

Adolescent and Young Adult Rheumatology Patient Reports of Reproductive Health Screening and Counseling in the Clinical Setting

Abstracts: Reproductive Issues in Rheumatic Disorders

4:00PM-5:30PM: Abstract Number: 1690

Apremilast Reduces Inflammation as Measured by MRI of the Hand in Patients with Psoriatic Arthritis: Primary Results from the Phase 4 MOSAIC Study

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: PsA

4:00PM-5:30PM: Abstract Number: 1672

Association of COVID-19 Vaccinations with Flares of Systemic Rheumatic Disease: A Case-Crossover Study

Abstracts: Infection-related Rheumatic Disease

4:00PM-5:30PM: Abstract Number: 1693

Blood Immunophenotyping Distinguishes Three Subgroups of Lupus Nephritis Patients with Distinct Kidney Infiltrates and Interferon Signatures

Abstracts: SLE – Diagnosis, Manifestations, & Outcomes II: Omics

4:00PM-5:30PM: Abstract Number: 1668

Cell Specific Molecular Profiling of Scleroderma Associated Interstitial Lung Disease Subtypes

Abstracts: Systemic Sclerosis & Related Disorders – Basic Science

4:00PM-5:30PM: Abstract Number: 1659

Cellular Deconstruction of Stromal and Myeloid Cell Compartments in the Inflamed Synovium of Juvenile Idiopathic Arthritis

Abstracts: Pediatric Rheumatology – Basic Science

4:00PM-5:30PM: Abstract Number: 1667

Characterization of the Vascular Niches in Systemic Sclerosis (SSc) as a Prototypical Immune-mediated Fibrotic Disease with Prominent Vasculopathy Using Imaging Mass Cytometry

Abstracts: Systemic Sclerosis & Related Disorders – Basic Science

4:00PM-5:30PM: Abstract Number: 1662

Chronic Excess IL-18 Induces NK Deficiency, but Drives Hyperinflammation via CD8 T-cell Cytokine Overproduction and Selective Immunodeficiency

Abstracts: Pediatric Rheumatology – Basic Science

4:00PM-5:30PM: Abstract Number: 1663

Clinically Severe Systemic Sclerosis Skin Harbors Inflammatory Fibroblasts Associated with Lymphocytes and Plasmacytoid Dendritic Cells

Abstracts: Systemic Sclerosis & Related Disorders – Basic Science

4:00PM-5:30PM: Abstract Number: 1678

Comparative Safety of Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs for Cancer in Rheumatoid Arthritis

Abstracts: RA – Treatments II: RA Treatment Safety

4:00PM-5:30PM: Abstract Number: 1689

Deep Cellular Immune Profiling in Psoriatic Arthritis Correlates with Imaging Phenotypes and Response to Targeted Advanced Therapy

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: PsA

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].